Creo Pharma
Creo Pharma (Zentiva Group) is a European generics and biosimilars manufacturer operating four production sites plus partner networks, serving 100 million+ people across 40+ countries with NHS-focused UK operations.
- Company typePrivate
- Founded2007
- HeadquartersDunmow, United Kingdom
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Creo Pharma does
Creo Pharma, as represented in the source material, is the UK-facing identity of Zentiva Group, a.s., a privately-held European pharmaceutical manufacturer headquartered in Prague, Czech Republic, with its UK office in Guildford. The group develops, produces, and distributes high-quality, affordable medicines across five product categories: retail generics, hospital generics, branded generics, value-added medicines, and biosimilars. Manufacturing is anchored in four internal production sites and supplemented by a broad network of external manufacturing partners, with the wholly-owned Swiss manufacturer Helvepharm AG adding adjacent capacity.
The company serves more than 100 million people in over 40 countries across Europe and Central Asia, with a wholly-owned subsidiary structure spanning 27+ markets (UK, Albania, Bosnia, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, Moldova, Montenegro, Netherlands, North Macedonia, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Ukraine, Kazakhstan) plus Switzerland. The workforce exceeds 5,400 professionals across 30+ countries. In the UK specifically, the company positions itself as an NHS-aligned supplier, working with NHS stakeholders across retail, hospital, and branded channels.
The business model is pharmaceutical supply: one-time product sales to public healthcare systems, hospitals, retail pharmacies, and wholesalers, plus an emerging B2B services layer covering API supply, out-licensing, contract development, contract manufacturing, and distribution partnerships. Revenue and pricing are not publicly disclosed. The customer base is dominated by national healthcare systems and institutional buyers; NHS UK is the only named end-customer relationship in the source material.
Creo Pharma firmographics
Firmographics- Name
- Creo Pharma
- Legal name
- Zentiva Group, a.s.
- Website
- https://creopharma.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Creo Pharma (Zentiva Group) is a European generics and biosimilars manufacturer operating four production sites plus partner networks, serving 100 million+ people across 40+ countries with NHS-focused UK operations.
- Ownership category
- akta.pro rank
Creo Pharma industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
- akta.pro secondary industry
- Generic Tender & Government Supply Markets (HLAIABAM)
Keywords
Where Creo Pharma is headquartered
LocationHeadquarters
- HQ city
- Dunmow
- HQ country
- United Kingdom
- HQ region
- Europe
Offices27 records
Markets served
Creo Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Generic Pharmaceuticals: Retail and hospital generics, branded generics, value-added medicines, and biosimilars designed to enhance access, improve outcomes, and reduce prescribing costs
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Creo Pharma product offering
Product offeringCore offering
Creo Pharma supplies generic, commercial brand, and specialist pharmaceutical products to the wholesale channel and to healthcare systems such as the NHS. The portfolio spans retail generics, hospital generics, branded generics, value-added medicines, and biosimilars designed to enhance access, improve outcomes, and reduce prescribing costs.
Product overview
The company develops, produces, and delivers high-quality, affordable medicines. The portfolio spans retail and hospital generics, branded generics, value-added medicines, and biosimilars—each designed to enhance access, improve outcomes, and reduce prescribing costs.
Differentiator
Problem solved
Functional benefit
Products and services
- Retail Generics
Quantifiable outcome
- Serves 100 million+ people
- +1 more outcomes
Companies that use Creo Pharma
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Creo Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Creo Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- External Manufacturing PartnerscoreBroad network of external manufacturing partners that work alongside four internal manufacturing sites to ensure supply security across European markets
Scale indicators4 records
Recent moves5 records
Expansion highlights4 records
Creo Pharma competitors and assessment
Company assessmentBroad incumbents
- Viatris: Formed from Mylan and Upjohn, Viatris is a major global off-patent pharmaceuticals player with extensive European generics presence and a comparable hospital/retail portfolio mix.
- Teva Pharmaceutical Industries: Global generics leader with deep European presence including the UK; competes with Zentiva across essentially every product category, but with significantly broader specialty and innovative portfolio.
Regional players
- Almirall: Spanish specialty pharma with branded generics and dermo-cosmetics focus; overlapping presence in several Southern European markets where Zentiva operates, though with a narrower therapeutic focus.
Emerging players
- Glenmark Pharmaceuticals: India-headquartered generics company with growing European branded generics footprint and biosimilars pipeline; competes on price and increasingly on differentiated formulations in overlapping European markets.
- Alvotech: Pure-play biosimilars developer and manufacturer with growing European commercialization footprint; competes specifically with Zentiva's biosimilars portfolio and is a likely partnering/acquisition target in the same space.
Direct peers
- Polpharma Group: Polish generics and API manufacturer with overlapping CEE presence and similar portfolio of retail/hospital generics, supplying European health systems under comparable cost-pressure dynamics.
- KRKA: Slovenian-headquartered generics manufacturer with a strong CEE and Eastern European footprint and a comparable product portfolio across prescription generics, branded generics, and value-added medicines.
- Sandoz: Spun out of Novartis, Sandoz is the world's largest pure-play generics and biosimilars company, directly competing with Zentiva in retail/hospital generics and biosimilars across European markets.
- Stada Arzneimittel: European-focused generic pharmaceuticals and consumer healthcare company with comparable portfolio of generics, branded generics, and biosimilars across retail and hospital channels; similarly PE-backed and operating at multi-country European scale.
- Accord Healthcare (Intas Pharmaceuticals): Intas-owned European generics subsidiary with a strong UK and EU hospital generics business, directly competing for NHS and continental hospital tenders alongside Zentiva.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Creo Pharma social profiles
Digital presenceCreo Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Creo Pharma leadership team
Management profileNumber of profiles
Creo Pharma subsidiaries and ownership
Company hierarchySubsidiaries29 records
Creo Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Creo Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Creo Pharma
What does Creo Pharma do?
Creo Pharma supplies generic, commercial brand, and specialist pharmaceutical products to the wholesale channel and to healthcare systems such as the NHS. The portfolio spans retail generics, hospital generics, branded generics, value-added medicines, and biosimilars designed to enhance access, improve outcomes, and reduce prescribing costs.
Is Creo Pharma a public or private company?
Creo Pharma is a private company. It is classified as unknown and is currently operating.
When was Creo Pharma founded?
Creo Pharma was founded in 2007. It employs 1,001 to 5,000 people.
Where is Creo Pharma based?
Creo Pharma is headquartered in Dunmow, United Kingdom, in the Europe region.
How does Creo Pharma make money?
One revenue line is on record: generic Pharmaceuticals.
Who are Creo Pharma's main competitors?
Broad incumbents on record are Viatris and Teva Pharmaceutical Industries. Almirall is listed as a regional player. Emerging players are Glenmark Pharmaceuticals and Alvotech. Direct peers are Polpharma Group, KRKA, Sandoz, Stada Arzneimittel and Accord Healthcare (Intas Pharmaceuticals).
Does Creo Pharma have an API?
No public API is recorded for Creo Pharma.
What industry is Creo Pharma in?
Creo Pharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIABAM, Generic Tender & Government Supply Markets. Its NAICS code is 325412 and its SIC code is 2834.